亞急性皮膚型紅斑狼瘡。以皮膚症狀為主的紅斑狼瘡特殊亞型,屬系統性紅斑鋃瘡和慢性盤狀紅斑狼瘡的中間型,是相對良性的全身性疾病皮膚損害,主要為丘疹鱗屑型,和環形多環形兩種形態,與SLE、DLE同樣有TYK2, IRF5 及CTLA4 genes的遺傳異常。多數伴隨anti-Ro/SSA autoantibodies,好發族群包括ancestral haplotype HLA1, B8, DR3, DQ2, DRw52 and C4 null, deficiencies of C1q, C2 and C4 components of complement 及TNF-α–308 polymorphism。主要分布在光照部位(頭頸部,V字部位)。亞急性皮膚型紅斑狼瘡可能由藥物誘發,包括胃藥(PPI)及抗黴菌藥terbinafine。奎寧是主要的治療, 使用此療法應戒煙以免影響療效。最近也有以 etanercept成功治療的報告。 Antihypertensives | 40/117(34·2%) | Calcium channel blockers | Diltiazem | 6 cases | Verapamil | 5 cases | Nifedipine | 3 cases | Nitrendipine | 1 case | Diuretics | Hydrochorothiazide | 10 cases | Hydrochlorothiazide + triamterene | 3 cases | Chlorthiazide | 2 cases | Beta blockers | Oxprenolo | 4 cases | Acebutolol | 1 case | Angiotensin-converting enzyme inhibitors | Enalapri | 2 cases | Lisnopril | 1 case | Captopril | 1 case | Cilazapril | 1 case | Antifungals | 30/117 (25·6%) | Terbinafine | 29 cases | Griseofulvin | 1 case | Chemotherapeutics | 10/117 (8·5%) | Docetaxe | 3 cases | Paclitaxel | 3 cases | Tamoxifen | 2 cases | Capecitabine | 2 cases | Antihistamines | 9/117 (7·7%) | Ranitidine | 7 cases | Brompheniramine | 1 case | Cinnarizine + thiethylperazine | 1 case | Immunomodulators | 8/117 (6·8%) | Leflunomide | 5 cases | Interferon α and β | 3 cases | Antiepileptics | 3/117 (2·6%) | Carbamazepine | 2 cases | Phenytoin | 1 case | Statins | 3/117 (2·6%) | Simvastatin | 2 cases | Pravastatin | 1 case | Biologics | 2/117 (1·7%) | Etanercept 50 | 1 case | Efalizumab | 1 case | Proton pump inhibitors | 2/117 (1·7%) | Lansoprazole | 2 cases | Nonsteroidal anti-inflammatory drugs | 2/117 (1·7%) | Naproxen | 1 case | Piroxicam | 1 case | Hormone-altering drugs | 2/117 (1·7%) | Leuprorelin | 1 case | Anastrozole | 1 case | Ultraviolet therapy | 2/117 (1·7%) | PUVA | 1 case | PUVA and UVB | 1 case | Others | 4/117 (3·4%) | Bupropion | 1 case | Tiotropium | 1 case | Ticlopidine | 1 case | Hay with fertilizer | 1 case | |